Agenus shareholders have suffered a modest ~13% loss since my last analysis, based on cash flow challenges and lack of near term catalysts. I examine the Q2/2025 earnings release and 10-Q to assess ...
CEO Garo Armen highlighted new BOT/BAL data validating durable responses in historically untreatable cold tumors, emphasizing, "we're talking about new data and more mature data." He announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results